Squarepoint
AUPH icon

Squarepoint’s Aurinia Pharmaceuticals AUPH Stock Holding History

Squarepoint’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-43,600
Closed -$392K – 4557
2024
Q4 		$392K Buy
+43,600
New +$356K ﹤0.01% 3942

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's AUPH Position: Q2 2026 in Review

Squarepoint reduced its Aurinia Pharmaceuticals (AUPH) stake by 0.74% in Q2 2026, selling an estimated $37.9K and leaving 317,430 shares worth $5.39M. The position accounts for 0.01% of the portfolio, ranked #1549.

Squarepoint first reported a position in AUPH in Q4 2019 and has held it in 16 quarters since. The position peaked at $7.08M in Q4 2025. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Squarepoint held 317,430 shares of Aurinia Pharmaceuticals worth $5.39M as of Q2 2026.
  • Squarepoint sold 2,374 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $37.9K.
  • Aurinia Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1549 holding.
  • Squarepoint first reported a position in Aurinia Pharmaceuticals in Q4 2019 and has held it in 16 quarters since.
  • Squarepoint's Aurinia Pharmaceuticals position peaked at $7.08M in Q4 2025.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.